Boehringer Ingelheim and Zai Lab, a Shanghai-based biopharmaceutical company, have signed a strategic cooperation agreement. Under the agreement, Boehringer Ingelheim will provide process optimization and manufacturing services for Zai Lab's new monoclonal antibody. The new monoclonal antibody will be used to treat autoimmune disease.

Boehringer Ingelheim China Biopharmaceutical Site, located in Zhangjiang, Shanghai, is the company's biologics manufacturing site in China, using mammalian cell culture technology for production and also provides contract manufacturing services. 

Source: Zai Lab